Post-market Surveillance for Medical Devices

Summary#

These final rules, SOR/2020-262, change the Food and Drug Regulations and the Medical Devices Regulations to strengthen how medical devices are watched after they reach the market. They give Health Canada new powers to order studies or assessments, require device-makers to send regular summary reports, and require faster notice about safety actions taken in certain foreign jurisdictions.

What it does#

• Gives the Minister power to order a device licence holder to carry out an assessment of a medical device when new information suggests its benefits or risks have changed. If the results are inadequate or the order is not followed, the Minister can suspend the licence.
• Lets the Minister order tests, studies or other activities when there are significant uncertainties about a device’s benefits or harms. The Minister must consider feasibility and less-burdensome options before ordering these activities.
• Requires holders of licences for Class II, III and IV devices to tell Health Canada about any serious risk information they learn from certain foreign regulators. That notice must be provided within 72 hours.
• Requires licence holders to prepare summary reports:
  • For Class II devices: every 24 months (biennial).
  • For Class III and IV devices: every 12 months (annual). These reports must analyze adverse effects, problems, incidents and serious foreign risk actions and must be kept for seven years.
• Changes incident-reporting rules so manufacturers and importers must report certain incidents that happen in Canada; for Class I devices some foreign-reporting rules remain unchanged.
• Allows the Minister to request targeted analyses from manufacturers (for Class I–IV as applicable) to help resolve safety or effectiveness questions.
• Replaces the fixed citation of the quality standard with an ambulatory reference to the National Standard CAN/CSA-ISO 13485, so Canada automatically refers to updates to that international quality standard.
• Limits which foreign regulators count for the new foreign-notification duty by using a published list (the “List of Regulatory Agencies…”), which currently contains 39 jurisdictions.

Key dates:

• Published in the Canada Gazette, Part II on December 23, 2020.
• Most of the rules come into force six months later (effectively June 23, 2021).
• The summary-report rules come into force on the first anniversary (December 23, 2021) to align with international timing.

Who's affected#

• Manufacturers and licence holders of medium- and higher-risk medical devices (Class II, III, IV) — they must prepare summary reports and respond to assessment or study orders.
• Importers and establishment licence holders — especially those importing Class II–IV devices, who must help report foreign safety actions.
• Manufacturers and importers of Class I devices — they keep some existing incident-reporting obligations; establishment licence holders importing Class I devices must attest to internal reporting procedures.
• Health care professionals in specific programs (some reporting duties were clarified or removed during consultations).
• The changes mostly affect device makers and the regulated industry; patients and clinicians may notice faster safety actions or communications.

Why it matters#

• Faster, clearer signals: Health Canada will get more timely and focused information about serious risks flagged by trusted foreign regulators. The 72‑hour rule is meant to speed up early protective action.
• Better evidence for decisions: The Minister can force an evidence-gathering assessment or ordered studies when real-world use raises new concerns. That can lead to label changes, suspensions, recalls or other protective steps.
• Ongoing manufacturer responsibility: Summary reports create a recurring, aggregated check by manufacturers on whether a device’s benefits and risks have changed.
• International alignment: Using an ambulatory reference to CAN/CSA-ISO 13485 reduces delays when the international quality standard changes and helps align Canada with other markets.
• Cost and burden: Health Canada estimates the package will cost industry about $921,060 per year on average, or about $6.87 million in present value over 10 years. The rules add administrative work (reporting and analyses) but Health Canada says many of the data and processes already exist under quality systems like ISO 13485.